DNA Form 144: Insider Plans to Sell 2,200 Shares Worth $24.6K on Jul 9 2025
Ginkgo Bioworks Holdings, Inc. (DNA) has filed a Form 144 indicating a proposed sale of 2,200 Class A shares through Fidelity Brokerage Services, valued at $24,596, with an expected trade date of 07/09/2025 on the NYSE.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ginkgo Bioworks Holdings, Inc. (DNA) has filed a Form 144 indicating a proposed sale of 2,200 Class A shares through Fidelity Brokerage Services, valued at $24,596, with an expected trade date of 07/09/2025 on the NYSE. The filing states that 46,344,630 shares are outstanding, meaning the contemplated sale represents roughly 0.005 % of the public float—well below the Rule 144 limit of 1 % or the average-daily-volume test.
The “Securities Sold During the Past 3 Months” table lists Austin Che as having executed 52 separate transactions of 99 shares each, totaling 5,148 shares between 04/09/2025 and 06/23/2025. No aggregate proceeds figure is supplied, but individual sales ranged from $567 to $941 per lot. The upcoming 2,200-share sale therefore continues a pattern of small, periodic dispositions.
No financial results, operational updates, or corporate events are disclosed in this notice. From a capital-markets perspective, the filing merely provides advance disclosure of a minor insider sale and does not alter the company’s fundamentals or capital structure.
Insights
TL;DR: Minor insider sale; immaterial to DNA’s float and unlikely to influence valuation.
The Form 144 covers 2,200 shares—only about 0.005 % of the 46.3 million shares outstanding—well within Rule 144 limits. Historical data show 5,148 shares sold over the prior three months, reinforcing that the insider has been methodically trimming a small position. No adverse information about operations is asserted in the filing, and the dollar amounts involved are de-minimis relative to DNA’s market capitalization. Accordingly, the disclosure is neutral from a market-impact standpoint and should not materially affect investor sentiment or liquidity.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the aggregate market value of the planned sale?
When is the insider planning to execute the sale?
Which broker will facilitate the transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.